MAZE
Maze Therapeutics, Inc.
36.73
+1.28 (+3.61%)
52w low 21.95
53.65 high
46.6% of range
Financial Analysis
| Ratio | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Operating Margin | -- | -- | -- | -- | -132.8% | -- | |
| EBITDA Margin | -- | -- | -- | -- | -114.5% | -- | |
| Net Margin | -- | -- | -- | -- | -121.0% | -- | |
| FCF Margin | -- | -- | -- | -- | -196.0% | -- | |
| Returns | |||||||
| Return on Equity | -- | -12.8% | -7.9% | -9.7% | -7.1% | -9.9% | |
| Return on Assets | -- | -11.1% | -7.1% | -8.7% | -5.8% | -8.4% | |
| Return on Inv Capital | -- | -12.8% | -8.7% | -10.7% | -4.8% | -7.0% | |
| Liquidity | |||||||
| Current Ratio | -- | 13.63x | 17.70x | 15.50x | 17.88x | 18.31x | |
| Quick Ratio | -- | 13.63x | 17.70x | 15.50x | 17.88x | 18.31x | |
| Cash Ratio | -- | 13.29x | 14.33x | 8.39x | 9.36x | 8.83x | |
| Leverage | |||||||
| Debt / Equity | -- | 0.10x | 0.06x | 0.07x | 0.18x | 0.13x | |
| Interest Coverage | -- | -- | -- | -- | -26.95x | -47.04x | |
| Equity Multiplier | -- | 1.16x | 1.11x | 1.12x | 1.23x | 1.17x | |
| Efficiency | |||||||
| Asset Turnover | -- | 0.00x | 0.00x | 0.00x | 0.05x | 0.00x | |
| Effective Tax Rate | -- | -0.0% | -0.0% | -0.0% | -- | -- | |
| Op CF / Net Income | -- | 0.89x | 0.82x | 0.80x | 1.62x | 0.34x | |
| Investment | |||||||
| Capex / Revenue | -- | -- | -- | -- | 0.5% | -- | |
| R&D / Revenue | -- | -- | -- | -- | 170.7% | -- | |
| SG&A / Revenue | -- | -- | -- | -- | 62.0% | -- | |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
-100.0%